WVE Wave Life Sciences Ltd.companySEC Filings & Insider Trading Activity 2026
Latest Wave Life Sciences Ltd. (WVE) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on April 28, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Wave Life Sciences Ltd. (WVE) (SEC CIK 1631574), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Clinical-stage biotech developing RNA medicines using proprietary PRISM® platform combining multi-modal RNA-targeting modalities and chemistry innovations
- • New emphasis on obesity program WVE-007 showing positive Phase 1 data with durable fat loss and muscle preservation, supporting once or twice yearly dosing
Risk Factors
- • Cybersecurity risk oversight by Audit Committee with quarterly updates on incidents and mitigation activities
- • Executive team including Data Security Officer and CFO with 50+ years combined cybersecurity experience managing risk
Management Discussion & Analysis
- • Revenue $42.7M in 2025 vs $108.3M in 2024, down $65.6M YoY due to Takeda agreement termination offset by GSK revenue increase
- • Operating loss widened to $215.4M in 2025 from $110.4M in 2024; operating margin -503.8% in 2025 vs -102.0% in 2024 (calculated as loss/ revenue)
Annual Reports Archive10-K
AI-powered analysis of Wave Life Sciences Ltd. (WVE) 10-K annual reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Wave Life Sciences Ltd. (WVE) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $3.6M | $113.3M | $108.3M | $42.7M |
| Operating Income | -$162.7M | -$68.0M | -$110.4M | -$215.4M |
| Net Income | -$161.8M | -$57.5M | -$97.0M | -$204.4M |
| Op. Margin | -4459.3% | -60.0% | -101.9% | -504.1% |
| Net Margin | -4434.7% | -50.8% | -89.6% | -478.3% |
| Balance Sheet | ||||
| Total Assets | $146.4M | $274.9M | $352.2M | $638.5M |
| Equity | -$45.1M | $39.6M | $209.5M | $518.4M |
| ROE | 358.9% | -145.1% | -46.3% | -39.4% |
Source: XBRL financial data from Wave Life Sciences Ltd. (WVE) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 28, 2026 | — | — | — |
8-K | Apr 21, 2026 | — | — | — |
8-K | Apr 15, 2026 | — | — | — |
8-K | Mar 26, 2026 | — | — | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 26, 2026 | — | Analysis | — |
8-K | Feb 2, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 11, 2025 | — | — | |
8-K | Dec 8, 2025 | — | — | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | — | |
10-Q | Jul 30, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Mar 4, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 12, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 10, 2024 | Mar 31, 2024 | — | |
10-K | Mar 6, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 3, 2023 | Mar 31, 2023 | — | |
10-K | Mar 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — |
Frequently Asked Questions
What are the latest WVE SEC filings in 2026?
Wave Life Sciences Ltd. (WVE) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did WVE file its most recent 10-K annual report?
Wave Life Sciences Ltd. (WVE) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view WVE 10-Q quarterly reports?
Wave Life Sciences Ltd. (WVE)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every WVE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has WVE filed recently?
Wave Life Sciences Ltd. (WVE)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find WVE insider trading activity (Form 4)?
SignalX aggregates every WVE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does WVE file with the SEC?
Wave Life Sciences Ltd. (WVE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new WVE filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Wave Life Sciences Ltd. (WVE).
What is WVE's SEC CIK number?
Wave Life Sciences Ltd. (WVE)'s SEC CIK (Central Index Key) number is 1631574. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1631574 to look up all WVE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find WVE return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Wave Life Sciences Ltd. (WVE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Wave Life Sciences Ltd. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 51+ filings.